What Medicare’s DMHT Codes Signal for Digital Therapeutics Reimbursement and Why Healthcare Is Paying Attention Digital therapeutics reimbursement refers to how public and private healthcare systems pay for evidence-based software …
Category:
News
-
-
France 2030 medical device funding is a major public investment opportunity for teams developing implantable medical devices and next-generation surgical robotics. Managed via Bpifrance under the France 2030 investment plan, …
-
How Reimbursement Actually Works in Poland This paper explains how reimbursement in Poland actually works for MedTech, IVD, digital health, and AI technologies — including the role of NFZ, DRGs …
-
Belgium’s DRG debate is often framed as a shift toward “case-based payment.” That description is technically correct but strategically misleading. In Belgium, DRGs are not a market-shaping instrument; they are …
-
How the New Coding and Payment Model Is Reshaping Hospital Care and Which Technologies Fit It Best For 2026, the German Hybrid-DRG system underwent a significant expansion, increasing to 69 …
-
Germany rarely announces a reimbursement change with fanfare. It tends to arrive indirectly through regulation, measurement, and administrative architecture. Sepsis is the latest example. From 1 January 2026, sepsis care …
-
Why “SaMD” Is the Wrong Place to Start On paper, Software as a Medical Device (SaMD) looks like progress.It gives artificial intelligence in healthcare a name, a definition, and a …
-
What age-based CA125 thresholds reveal about winning adoption in NHS cancer pathways NICE Redefines Ovarian Cancer Testing More women with ovarian cancer in England could be diagnosed earlier and more …
-
The HAS / CNEDiMTS route explained science, law, and real-world decisions France operates one of the most structured and evidence-based reimbursement systems for medical devices in Europe. Access is not …
-
MedTech / IVD VC Funding: the investor is modelling reimbursement physics, not admiring your science Most founders pitch MedTech as if capital is attracted by novelty. In regulated healthcare, the …